In a report released today, Steven Mah from TD Cowen maintained a Buy rating on 908 Devices (MASS – Research Report). The company’s shares opened today at $7.04.
Mah covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Codexis, and BioLife Solutions. According to TipRanks, Mah has an average return of -8.9% and a 31.21% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 908 Devices.
See today’s best-performing stocks on TipRanks >>
MASS market cap is currently $234.1M and has a P/E ratio of -5.98.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MASS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
908 Devices (MASS) Company Description:
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets.
Read More on MASS:
